Published in Cancer Cell on January 07, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Mitochondria and cancer. Nat Rev Cancer (2012) 4.81
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol (2013) 2.42
Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol (2014) 2.37
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell (2015) 2.20
Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res (2013) 2.19
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell (2014) 1.98
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet (2014) 1.94
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood (2011) 1.67
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia (2012) 1.64
DNA methylation presents distinct binding sites for human transcription factors. Elife (2013) 1.63
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res (2012) 1.63
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res (2010) 1.49
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet (2011) 1.47
Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas. Epigenetics (2011) 1.44
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia (2014) 1.38
Library-free methylation sequencing with bisulfite padlock probes. Nat Methods (2012) 1.37
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol (2013) 1.34
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov (2012) 1.33
Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer (2011) 1.32
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep (2014) 1.31
The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget (2015) 1.27
An optimized algorithm for detecting and annotating regional differential methylation. BMC Bioinformatics (2013) 1.27
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol (2014) 1.23
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med (2010) 1.23
MethylSig: a whole genome DNA methylation analysis pipeline. Bioinformatics (2014) 1.22
Epigenetic roles of MLL oncoproteins are dependent on NF-κB. Cancer Cell (2013) 1.20
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest (2013) 1.19
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell (2012) 1.19
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol (2011) 1.18
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog (2011) 1.15
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One (2010) 1.15
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia (2013) 1.11
Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res (2014) 1.09
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med (2013) 1.09
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol (2013) 1.07
Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol (2011) 1.05
Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep (2012) 1.04
Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer (2010) 1.04
Epigenetic regulation by RARα maintains ligand-independent transcriptional activity. Nucleic Acids Res (2011) 1.03
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Concise review: Leukemia stem cells in personalized medicine. Stem Cells (2014) 1.02
Pan-cancer patterns of DNA methylation. Genome Med (2014) 1.02
DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A (2014) 1.02
Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood (2015) 1.01
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med (2016) 1.01
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood (2012) 1.01
Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics (2014) 1.01
Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res (2015) 1.00
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One (2012) 0.99
Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS One (2012) 0.99
Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats. PLoS One (2012) 0.99
Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene (2015) 0.99
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem (2011) 0.97
Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol (2014) 0.97
Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biol (2015) 0.96
Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer (2011) 0.96
C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis. Proc Natl Acad Sci U S A (2014) 0.95
DNA methylation profiling using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP). Methods (2010) 0.94
The epigenetic landscape of acute myeloid leukemia. Adv Hematol (2014) 0.94
Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun (2015) 0.93
Identification of DNA methylation changes at cis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencing. Cell Cycle (2014) 0.93
Epigenetic Aging Signatures Are Coherently Modified in Cancer. PLoS Genet (2015) 0.92
Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol (2013) 0.92
High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. J Biol Chem (2013) 0.91
The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell (2013) 0.90
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Med (2014) 0.89
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia (2015) 0.89
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget (2016) 0.88
A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia. Clin Cancer Res (2011) 0.88
Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma. Biomed Rep (2013) 0.88
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest (2014) 0.88
Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells. Leukemia (2013) 0.87
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood (2016) 0.87
Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood (2014) 0.87
Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med (2016) 0.87
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget (2011) 0.86
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell (1992) 27.80
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Simultaneous inference in general parametric models. Biom J (2008) 23.64
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood (2006) 5.43
Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol (2000) 5.34
Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev (1988) 4.02
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
Methylation profiling in acute myeloid leukemia. Blood (2001) 2.22
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood (2009) 1.75
Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods Mol Biol (2009) 1.71
p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood (1999) 1.71
Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia (2003) 1.63
C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol (2006) 1.60
Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res (2005) 1.33
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Minimum information requested in the annotation of biochemical models (MIRIAM). Nat Biotechnol (2005) 10.66
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences. Nature (2007) 7.91
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med (2003) 4.90
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
LINE-1 activity in facultative heterochromatin formation during X chromosome inactivation. Cell (2010) 3.70
Therapeutic advances in acute myeloid leukemia. J Clin Oncol (2011) 3.69
Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology (2009) 3.66
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology (2013) 3.45
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res (2003) 3.34
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Epigenomics: beyond CpG islands. Nat Rev Genet (2004) 3.21
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg (2009) 2.93
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc Natl Acad Sci U S A (2006) 2.89
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology (2014) 2.73
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood (2012) 2.56
Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev (2004) 2.56
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics (2004) 2.55
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood (2012) 2.55
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging (1999) 2.43
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40